Organoids And Spheroids Market Size
| Study Period | 2019 - 2030 |
| Market Size (2025) | USD 1.13 Billion |
| Market Size (2030) | USD 2.26 Billion |
| CAGR (2025 - 2030) | 14.98% |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
| Market Concentration | Medium |
Major Players*Disclaimer: Major Players sorted in no particular order |
Organoids And Spheroids Market Analysis
The Organoids And Spheroids Market size is estimated at USD 1.13 billion in 2025, and is expected to reach USD 2.26 billion by 2030, at a CAGR of 14.98% during the forecast period (2025-2030).
Organoids are 3D, lab-grown miniatures that mimic the structure and function of real organs, derived from stem cells or progenitor cells to model tissues like the liver, brain, or kidneys for research on organ development and disease. In contrast, spheroids are simpler 3D cell aggregates that form in suspension and are used to study basic cellular behaviors such as growth and drug responses. The organoids and spheroids market is experiencing dynamic growth fueled by advancements in 3D cell culture technology and a growing focus on personalized medicine.
Innovations in single-particle isolation and dispensing are crucial in this development, significantly impacting research and applications in drug discovery, personalized medicine, and regenerative therapies. For instance, in July 2024, SEED Biosciences introduced Dispen3D, a key advancement in single-particle dispensing technology. This cutting-edge platform utilizes impedance-based dispensing technology and advanced data analysis software to precisely and gently handle 3D cellular models, including spheroids and organoids. By enabling high-precision isolation and dispensing, Dispen3D offers researchers a powerful tool for conducting detailed experiments and accelerating the transition from traditional animal models to sophisticated 3D models. Therefore, such innovative technology enhances research capabilities that drive the growth of the organoids and spheroids market.
Moreover, colorectal cancer (CRC) is a complex and heterogeneous disease, and advancements in three-dimensional (3D) culture models have proven inadequate for accurately studying its molecular characteristics and drug responses. For instance, in a study published in the Journal of Exploration of Targeted Anti-tumor Therapy in April 2024, spheroids derived from dissociated CRC cells or tissues better mimicked the tumor microenvironment (TME). They demonstrated increased chemoresistance compared to 2D models, as seen in co-culture studies with fibroblasts and cancer-associated fibroblasts (CAFs). Also, co-cultured CRC spheroids with fibroblasts showed reduced drug sensitivity to 5-FU and regorafenib, reflecting clinical conditions more closely than 2D models.
Additionally, per the same source mentioned above, organoids, which can be developed from normal and cancerous colonic tissues, retain the genomic and phenotypic heterogeneity of primary tumors, making them a promising tool for drug screening and personalized medicine. Therefore, such studies represent a significant improvement and are expected to grow, driving market expansion.
The organoids and spheroids market is experiencing rapid growth as advanced 3D cell culture models become increasingly vital for drug discovery, disease modeling, and toxicity testing. For instance, in March 2023, MIMETAS launched OrganoReady colon and kidney organoid tubules, which offer assay-ready, donor-relevant 3D models that provide a more accurate representation of human tissues without needing stem cell reprogramming. The collaboration with HUB Organoid Technology and the use of MIMETAS’ proprietary OrganoPlate microfluidic platform enables the creation of perfused tubular organoids, ideal for applications like mechanistic toxicology and drug-induced organ injury testing, aligning with the FDA Modernization Act 2.0. Thus, such rising launches accelerate the adoption of organoids and spheroids in the pharmaceutical and biotech industries, thus driving market growth.
However, the high cost of technology, stringent regulatory scenario, and standardization challenges restrain market growth.
Organoids And Spheroids Market Trends
Personalized Medicine Segment is Expected to Witness Significant Growth Over the Forecast Period
Personalized medicine uses these 3D cell culture technologies to tailor medical treatments to individual patients based on their unique biological characteristics. Personalized medicine aims to improve the accuracy of drug testing, predict patient responses to therapies, and optimize treatment plans, thereby enhancing the efficacy and safety of medical interventions.
The organoids and spheroids market is rapidly advancing, with personalized medicine becoming a major focus, particularly in cancer treatment. Recent research highlights their potential in guiding individualized treatments, as organoids significantly reduce tumor heterogeneity and provide a more accurate platform for drug sensitivity testing. For instance, a study published in Cell Communication and Signaling in December 2023 highlighted that lung cancer organoids (LCOs) could predict drug sensitivity with over 80% concordance rates in advanced lung cancer, though accuracy varied with drug types. These findings underscore the growing role of organoids in enabling personalized treatment approaches used to study lung cancer.
Further, as clinical trials and studies progress, lung cancer organoids hold promise for improving outcomes in precision medicine, offering more reliable, patient-specific therapeutic strategies. As the market continues to evolve, this is expected to drive the organoids and spheroids market in the coming years.
The organoids and spheroids market is evolving rapidly, with personalized medicine emerging as a key application area. For instance, in May 2024, an international research team, including the Institute of Grenoble (CEA-Irig) and CEA-Leti, achieved a milestone in this field, which reported the first complete vascularization of organoids on a microfluidic chip. This breakthrough allows organoids to develop functional blood vessel networks, significantly improving their maturation and long-term viability. By replicating blood flow conditions, this innovation enables more realistic and effective models for drug discovery, regenerative medicine, and personalized therapeutic approaches. As the technology scales, it promises to advance the role of organoids in creating tailored treatments, thereby revolutionizing personalized medicine.
Such innovation enhances the relevance of organoid models in personalized medicine, which, in turn, drives the market’s growth in the forecasted period.
Hence, there is an increasing demand for targeted therapies and advancing precision medicine, which is expected to drive the personalized medicine segment within the market.
North America is Expected to Dominate the Organoids and Spheroids Market
North America leads the organoids and spheroids market primarily due to advanced biotechnological solutions for drug development and personalized medicine. The increase in innovations in organoid technology and rising strategic developments by companies is expected to drive the market's growth in the region.
The organoids and spheroids market in the United States is experiencing significant advancements, particularly in the realm of cancer research. Epithelial ovarian cancer (EOC) represents a critical area of study due to its complex metastatic progression involving spheroids. For instance, a study published in the American Association for Cancer Research in March 2024 and a special conference on ovarian cancer in 2023 highlighted using spheroid and organoid models to explore EOC pathobiology. Using high-grade serous and ascites-derived iOvCa cell lines, scientists generated spheroids and organoids to investigate differences in morphology, growth dynamics, and bioenergetic stress. This study found that EOC spheroids often presented as compact clusters with unique molecular adaptations compared to organoids, which exhibited heterogeneous morphologies.
Such findings emphasize the importance of incorporating spheroid and organoid systems in preclinical research, and the integration of these advanced models is poised to drive innovation in precision medicine and enhance therapeutic strategies in the United States organoids and spheroids market, contributing to sustained market growth and innovation.
Moreover, creating a cutting-edge micro-physiological system to establish and monitor vascular networks within 3D cell aggregates, including spheroids and organoids, will shape the market's future. For instance, a study published in Nature Communications in February 2024 highlighted that research supported by various Canadian and international funding bodies, including the Canadian Foundation for Innovation and the Natural Sciences and Engineering Research Council, designed a new platform that supports the growth of endothelial networks around mesenchymal and pancreatic islet spheroids and blood vessel organoids, enables functional intravascular perfusion and enhances organoid maturation and function, thereby driving the market’s growth in the country.
Further, companies are highly focused on advancement and highlight significant strides in scaling up production capabilities. For instance, in July 2023, Molecular Devices LLC developed its patent-pending bioprocess technology designed to produce tens of millions of quality-controlled organoids per batch. This innovation, part of the company's expanded organoid line services, utilizes proprietary bioreactor technology to scale the production of standardized, assay-ready organoids from customer-supplied lines or patient-derived xenografts (PDX). The growing ability to produce large quantities of consistent, ready-to-use organoids drives drug discovery advancements and improves research efficiency, contributing to sustained market growth in the region.
Therefore, the focus of established players is on technological advancements and the rising adoption of organoids and spheroids. Owing to these factors, North America is expected to lead the organoids and spheroids market.
Organoids And Spheroids Market Industry Overview
The organoids and spheroids market is slightly consolidated due to the dominance of a few global companies with significant market share, driven by their advanced technologies and strong R&D capabilities. At the same time, smaller players contribute to innovation in niche areas. The key strategies market participants adopt are launches, significant contributions from established life science companies, innovative startups, and expansions to expand their footprint. The major players in the market include Thermo Fisher Scientific Inc., Merck KGaA (MilliporeSigma), Corning Incorporated, STEMCELL Technologies Inc., Greiner Bio-One International GmbH, Hubrecht Organoid Technology (HUB), Crown Bioscience Inc., DefiniGEN, Cellesce Ltd, and InSphero AG.
Organoids And Spheroids Market Leaders
-
Cellesce Ltd.
-
InSphero AG
-
STEMCELL Technologies Inc.
-
Corning Incorporated
-
Thermo Fisher Scientific Inc.
- *Disclaimer: Major Players sorted in no particular order
Organoids And Spheroids Market News
- June 2024: Molecular Devices LLC inaugurated a state-of-the-art manufacturing facility in Cardiff, United Kingdom. This multi-million-pound site is designed specifically to support the company's proprietary bioprocess workflow and advanced bioreactor technology, which are pivotal for the large-scale, quality-controlled production of patient-derived organoids (PDOs). The new facility will enable the generation of high volumes of 3D Ready PDOs, which are cryopreserved in an assay-ready format for immediate use by researchers. This development represents a significant advancement in the market, offering services that enhance reproducibility and accessibility for high-throughput drug discovery and personalized medicine applications.
- April 2023: InSphero AG expanded its reach into the Indian market by signing a distribution agreement with Bionova Supplies. This partnership will make InSphero’s patented Akura 96 and 384 Spheroid Microplates available to researchers across India. The agreement is set to enhance the development and application of spheroid and organoid cultures in the region, leveraging Bionova Supplies’ established presence as a leading provider of biotechnology and scientific instruments in India. This strategic move underscores InSphero's commitment to advancing research and accelerating innovation in 3D cell culture technologies globally.
Organoids And Spheroids Market Industry Segmentation
Organoids are 3D mini-organs grown from stem cells that mimic organ structure and function and are used for research on development and disease. Spheroids are simpler 3D cell clusters that study cellular behaviors like growth and drug responses.
The organoids and spheroids market is segmented into type, application, end user, and geography. By type, the market is segmented into organoids (intestinal organoids, hepatic organoids, pancreatic organoids, neural organoids, and other organoids {lung, kidney, and gastric, among others}) and spheroids (multicellular tumor spheroids, neurospheres, hepatospheres, mammospheres, and other spheroids {embryoid bodies, etc.}), application (disease modeling, drug discovery and toxicology screening, regenerative medicine, stem cell research, personalized medicine, and other applications {gene editing and immuno-oncology, among others}), end user (pharmaceutical and biotechnology companies, academic and research institutes, hospitals and diagnostic centers, contract research organizations {CROs}, and other end users {biobanks, stem cell banks}). By geography, the market is segmented into North America, Europe, Asia-Pacific, South America, and Middle East and Africa. The report also offers the market size and forecasts for 17 countries across the region. For each segment, the market sizing and forecasts were made on the basis of value (USD).
| By Type | Organoids | Intestinal Organoids | |
| Hepatic Organoids | |||
| Pancreatic Organoids | |||
| Neural Organoids | |||
| Other Organoids | |||
| Spheroids | Multicellular Tumor Spheroids | ||
| Neurospheres | |||
| Hepatospheres | |||
| Mammospheres | |||
| Other Spheroids | |||
| By Application | Disease Modeling | ||
| Drug Discovery & Toxicology Screening | |||
| Regenerative Medicine | |||
| Stem Cell Research | |||
| Personalized Medicine | |||
| Other Applications | |||
| By End User | Pharmaceutical & Biotechnology Companies | ||
| Academic & Research Institutes | |||
| Hospitals and Diagnostic Centers | |||
| Contract Research Organizations (CROs) | |||
| Other End Users | |||
| By Geography | North America | United States | |
| Canada | |||
| Mexico | |||
| Europe | Germany | ||
| United Kingdom | |||
| France | |||
| Italy | |||
| Spain | |||
| Rest of Europe | |||
| Asia-Pacific | China | ||
| Japan | |||
| India | |||
| Australia | |||
| South Korea | |||
| Rest of Asia-Pacific | |||
| Middle East and Africa | GCC | ||
| South Africa | |||
| Rest of Middle East and Africa | |||
| South America | Brazil | ||
| Argentina | |||
| Rest of South America | |||
| Organoids | Intestinal Organoids |
| Hepatic Organoids | |
| Pancreatic Organoids | |
| Neural Organoids | |
| Other Organoids | |
| Spheroids | Multicellular Tumor Spheroids |
| Neurospheres | |
| Hepatospheres | |
| Mammospheres | |
| Other Spheroids |
| Disease Modeling |
| Drug Discovery & Toxicology Screening |
| Regenerative Medicine |
| Stem Cell Research |
| Personalized Medicine |
| Other Applications |
| Pharmaceutical & Biotechnology Companies |
| Academic & Research Institutes |
| Hospitals and Diagnostic Centers |
| Contract Research Organizations (CROs) |
| Other End Users |
| North America | United States |
| Canada | |
| Mexico | |
| Europe | Germany |
| United Kingdom | |
| France | |
| Italy | |
| Spain | |
| Rest of Europe | |
| Asia-Pacific | China |
| Japan | |
| India | |
| Australia | |
| South Korea | |
| Rest of Asia-Pacific | |
| Middle East and Africa | GCC |
| South Africa | |
| Rest of Middle East and Africa | |
| South America | Brazil |
| Argentina | |
| Rest of South America |
Organoids And Spheroids Market Research FAQs
How big is the Organoids And Spheroids Market?
The Organoids And Spheroids Market size is expected to reach USD 1.13 billion in 2025 and grow at a CAGR of 14.98% to reach USD 2.26 billion by 2030.
What is the current Organoids And Spheroids Market size?
In 2025, the Organoids And Spheroids Market size is expected to reach USD 1.13 billion.
Who are the key players in Organoids And Spheroids Market?
Cellesce Ltd., InSphero AG, STEMCELL Technologies Inc., Corning Incorporated and Thermo Fisher Scientific Inc. are the major companies operating in the Organoids And Spheroids Market.
Which is the fastest growing region in Organoids And Spheroids Market?
Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2025-2030).
Which region has the biggest share in Organoids And Spheroids Market?
In 2025, the North America accounts for the largest market share in Organoids And Spheroids Market.
What years does this Organoids And Spheroids Market cover, and what was the market size in 2024?
In 2024, the Organoids And Spheroids Market size was estimated at USD 0.96 billion. The report covers the Organoids And Spheroids Market historical market size for years: 2019, 2020, 2021, 2022, 2023 and 2024. The report also forecasts the Organoids And Spheroids Market size for years: 2025, 2026, 2027, 2028, 2029 and 2030.
Organoids And Spheroids Industry Report
Statistics for the 2025 Organoids And Spheroids market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Organoids And Spheroids analysis includes a market forecast outlook for 2025 to 2030 and historical overview. Get a sample of this industry analysis as a free report PDF download.
